Vernalis

About

Vernalis collaborates with a wide range of organisations to enable drug discovery programs through both short- and long-term projects. By applying their deep and wide expertise in structure-based drug discovery, built over twenty-five years of partnerships and innovation to enable challenging targets, they can express and engineer your proteins, find and validate hits and help to evolve your chemical series into pre-clinical candidates. And they can do all this in-house at their fully equipped laboratories in Cambridge UK.

Company Type

ViaNautis

About

ViaNautis swas spun out of UCL from the laboratories of Prof. Giueseppe Battaglia in 2018. 

Following a successful, oversubscribed late seed funding, the company now works from labs at the Babraham Research Campus. The company’s proprietary technology, PolyNaut® can be applied to both clinical and non clinical/ex vivo products.

ViaNautis works with pharma and biotech partners for innovation and problem solving in neurology, oncology and immune diseases. Our partners Abcam PLC market and develop non-clinical products.

Company Type
X Account
@ViaNautis

Viramal

About

Viramal - Transformative medicine for women

Viramal is a specialist pharma company based in the UK, with a subsidiary in Sweden developing a portfolio of transformative healthcare products for women.

Viramal believes that there is a significant unmet medical need in women's sexual and reproductive health.

We exist to help make the lives of women everywhere, better.

Company Type

Vitarka Therapeutics

About

A female-led preclinical biotech start-up, Vitarka Therapeutics is focused on revolutionising the market for non-viral drug delivery technology. The company is developing combination medicines using RNAi therapies and a non-viral drug delivery platform. Their novel tumour-targeted platform technology, EndoPore, targets solid tumours and delivers therapeutics for intracellular targets.

Company Type